Tag Archives: BIO Investor Forum

Plan Now to Attend the 15th Annual BIO Investor Forum Oct 18-19, San Francisco

The BIO Investor Forum, now in its 15th year, is open for registration. An international conference with plenary sessions, business roundtables, company presentations, therapeutic workshops, networking opportunities and partnering meetings, it is designed to help early-stage companies find sources of capital. Attendees will have opportunities to learn about the latest investment trends as well as showcase their company to qualified investors. BIO is pleased to announce that Rachel Haurwitz, PhD, CEO of Caribou Biosciences, will Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Haves and Have Nots in Biotech Venture Capital

US_VC_Funding_2009_2014

Recent data from the BIO Industry Analysis team tells a story of “haves and have-nots” in US biopharma venture capital. Three key findings were discussed Wednesday at the 14th Annual BIO Investor Forum. The first finding from the recent study is that funding of therapeutic companies is strong for late rounds (Series B and above), but weak for Series A. Although total levels of venture funding have been climbing recently, the majority of the increase is from late rounds. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

Fireside Chat: “Everything we knew in science 10 years ago is wrong.”

admin-ajax.php-2

The speed of scientific innovation these days is comparable to the PC innovation era of the 1980s, according to Robert Nelsen of ARCH Venture Partners at today’s BIO Investor Forum fireside chat. This is not to say that he feels investing in biopharma is a short term game. Robert urged the audience to “keep their faith” in good science and the “good ideas will percolate up” to yield innovative breakthroughs. Having played a significant role Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Stretching Your Dollar: Methods and Tools for Increasing the Productivity of Clinical Trials

admin-ajax.php

Recent Tufts data show clinical trials typically take nearly twice as long to complete enrollment as predicted at launch and 48% of trial sites miss enrollment targets.  Delays in trials shrink the returns from patent exclusivity and increase R&D costs.  New methods such as adaptive and batch trial designs, as well as explosive growth in digital tools, such as Apple’s ResearchKit, have transformed the trial design choices available.  These innovations, and others, provide new levers Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Fireside Chat: James Noble Says Go for IPO

james-noble1

“Go for it,” was the parting advice James Noble, CEO and co-founder of Adaptimmune, had for pre-IPO biotech companies attending today’s BIO Investor Forum fireside chat. But, he said, be prepared for scrutiny from all sides… and mountains of paperwork. James co-founded Adaptimmune, a clinical-stage immunotherapy biopharmaceutical company, in July of 2008. At that time he was also part-time CEO of Immunocore, also a clinical-stage company engaged in T-cell receptor researches and develop. From this Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,